Feed INVA
IN
Innoviva, Inc. INVA · NASDAQ
$21.22 -0.42% (-$0.09)
Depth
- Market cap
- $1.54B
- Enterprise value
- $1.24B
- P/E
- 4.3x
- Forward P/E
- 7.5x
- PEG
- 0.0x
- P/S
- 3.5x
- P/FCF
- 8.2x
- EV/EBITDA
- 1.5x
- ROIC
- 8.4%
- Gross margin
- 73.1%
- Net margin
- 80.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.4x
- Beta
- 0.33
- Free float
- 93.6%
Sector
Healthcare
Industry
Biotechnology
CEO
Pavel Raifeld
Employees
159
Headquarters
Burlingame
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 12% a year over the last 3 years.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 81 USD is left as net profit.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $570.4M against $269.7M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number